Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Alopecia Mucinosa
8%
Arm
7%
Breast Cancer
100%
Capecitabine
9%
Carboplatin
5%
Chemotherapy
35%
Circulating Tumor Cell
5%
Clinical Feature
5%
Clinical Trial
5%
Disease Exacerbation
8%
Disease Free Survival
9%
Diseases
11%
Docetaxel
16%
Epidermal Growth Factor Receptor 2
26%
Eribulin
8%
Estrogen Receptor
10%
Exemestane
6%
Gamma Urogastrone
29%
Gemcitabine
10%
Genetics
11%
Gonadorelin Agonist
6%
Hazard Ratio
18%
Hormone Receptor
31%
Hormone Therapy
12%
Immunotherapy
6%
Letrozole
6%
Malignant Neoplasm
10%
Median Follow Up
7%
Metastatic Breast Cancer
49%
Neoadjuvant Chemotherapy
14%
Neoplasm
7%
Overall Survival
24%
Palbociclib
13%
Pertuzumab
11%
Prediction Model
6%
Premenopause
8%
Prevalence
12%
Prognostic Factor
7%
Progression Free Survival
20%
Prospective Cohort Study
9%
Radiation Therapy
8%
Randomized Controlled Trial
5%
Real-World Evidence
8%
Recurrence Free Survival
7%
Recurrent Disease
8%
Survival Rate
7%
Symptomatic Treatment
6%
Trastuzumab
15%
Triple Negative Breast Cancer
16%
Tumor
6%
Biochemistry, Genetics and Molecular Biology
BRCA1
11%
BRCA2
9%
Clinical Trial
7%
CXCL13
5%
Cytokine
5%
Deep Sequencing
5%
Deficiency
5%
Disease Free Survival
9%
Epidermal Growth Factor Receptor
24%
Estrogen Receptor
8%
Gemcitabine
5%
Gene Expression
10%
Gene Expression Profiling
9%
Gene Mutation
10%
Genomics
28%
Germ Cell
9%
Germline
8%
Homologous Recombination
6%
Hormone Receptor
11%
Immune Checkpoint Inhibitor
6%
Immune Response
6%
Messenger RNA
7%
Multi-Omics
7%
Multivariate Analysis
7%
Mutated Genes
5%
Overall Survival
24%
Prevalence
9%
Progression Free Survival
9%
Recombination Repair
5%
Recurrence Free Survival
5%
RNA Sequencing
6%
Somatic Mutation
5%
Survival Rate
9%
Tumor-Infiltrating Lymphocytes
5%
Vascular Endothelial Growth Factor A
5%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
5%
Atezolizumab
5%
Breast Cancer
23%
Carboplatin
5%
Chemotherapy Regimen
22%
Disease Free Survival
5%
Diseases
5%
Docetaxel
14%
Epidermal Growth Factor Receptor 2
17%
Eribulin
8%
First-Line Chemotherapy
5%
Gamma Urogastrone
17%
Gemcitabine
7%
Hormone Receptor
12%
Malignant Neoplasm
9%
Metastatic Breast Cancer
29%
Overall Survival
8%
Paclitaxel
5%
Palbociclib
5%
Pegfilgrastim
5%
Pertuzumab
11%
Phase II Trials
5%
Progression Free Survival
10%
Trastuzumab
11%
Triple Negative Breast Cancer
6%